Advertisement

Clinical and Experimental Medicine

, Volume 18, Issue 4, pp 535–546 | Cite as

Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study

  • Nahla E. El-Ashmawy
  • Enas A. El-Zamarany
  • Eman G. Khedr
  • Hoda A. El-Bahrawy
  • Ola A. El-Feky
Original Article

Abstract

Hepatocellular carcinoma (HCC) is one of the major health problems in the world. DCs-based vaccines are a promising immunotherapeutic strategy that aims at the optimal for induction of a specific antitumor immune response and destruction of tumor cells. The present study was conducted to investigate the immunogenic characters of whole tumor lysate-pulsed DCs vaccine and its ability to induce a specific antitumor immune response in HCC mice model. We also evaluate the effectiveness of prophylactic and therapeutic immunization strategies against HCC in mice models. Mice-derived DCs were in vitro loaded with whole tumor lysate prepared from liver tissue of HCC mice and evaluated for expression of surface maturation markers CD83 and CD86. In vivo immunization of mice with whole tumor lysate-pulsed DCs was performed in two strategies; prophylactic (pre-exposure to HCC) and therapeutic (post-exposure to HCC). Effectiveness of both protocols was investigated in terms of histopathological examination of liver sections and measurement of serum levels of immune cytokines interferon-γ (IFN-γ) and interleukin-2 (IL-2). Loading of DCs with whole tumor cell lysate exhibited a significant increase in expression of CD83 and CD86. In vivo administration of prophylactic doses of whole tumor lysate-pulsed DCs in mice before induction of HCC evokes a strong antitumor immune response presented by absence of malignant cells in liver sections and the significant increase in IFN-γ and IL-2. Data herein indicated that prophylactic vaccination with whole tumor lysate-pulsed DCs exhibited an effective antitumor immune response against HCC more than therapeutic protocol.

Keywords

Hepatocellular carcinoma Dendritic cells IFN-γ IL-2 Prophylactic vaccine 

Abbreviations

CTLs

Cytotoxic T-lymphocytes

DCs

Dendritic cells

GM-CSF

Granulocyte macrophage colony-stimulating factor

HCC

Hepatocellular carcinoma

IL-4

Interleukin-4

IL-2

Interleukin-2

IFN-γ

Interferon-γ

PBMN

Peripheral blood monocytes

TAAs

Tumor-associated antigens

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures involving animals were performed in accordance with institutional guidelines and with the approval of the Research Ethics Committee of Faculty of Pharmacy, Tanta University.

Informed consent

No human subjects in this research.

References

  1. 1.
    Greten TF, Duffy AG, Korangy F. Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res. 2013;19(24):6678–85.CrossRefGoogle Scholar
  2. 2.
    Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39:38–48.CrossRefGoogle Scholar
  3. 3.
    Han Y, Wu Y, Yang C, et al. Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy. J Transl Med. 2017;15(1):64.CrossRefGoogle Scholar
  4. 4.
    Miamen AG, Dong H, RoMiamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer. 2012;1(3–4):226–37.CrossRefGoogle Scholar
  5. 5.
    Rai V, Abdo J, Alsuwaidan AN, Agrawal S, Sharma P, Agrawal DK. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Mol Cell Biochem. 2017.  https://doi.org/10.1007/s11010-017-3092-z.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Takahara A, Koido S, Ito M, et al. Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol Immunother. 2011;60:1289–97.CrossRefGoogle Scholar
  7. 7.
    Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol. 2018;200(2):443–9.CrossRefGoogle Scholar
  8. 8.
    Hutten TJ, Thordardottir S, Fredrix H, et al. CLEC12A-mediated antigen uptake and cross-presentation by human dendritic cell subsets efficiently boost tumor-reactive T cell responses. J Immunol. 2016;197(7):2715–25.CrossRefGoogle Scholar
  9. 9.
    Cohn L, Delamarre L. Dendritic cell-targeted vaccines. Front Immunol. 2014;5:255.CrossRefGoogle Scholar
  10. 10.
    Wang W-H, Zhou C-H, Ding J, et al. Immune effect and safety evaluation of vaccine prepared by dendritic cells modified by rAAV-carrying BCSG1 gene. Gene Ther. 2016;23:839–45.CrossRefGoogle Scholar
  11. 11.
    Kajihara M, Takakura K, Ohkusa T, Koido S. The impact of dendritic cell-tumor fusion cells on cancer vaccines-past progress and future strategies. Immunotherapy. 2015;7:1111–22.CrossRefGoogle Scholar
  12. 12.
    Lin C-F, Lin C-M, Lee K-Y, et al. Escape from IFN-γ-dependent immunosurveillance in tumorigenesis. J Biomed Sci. 2017;24:10.CrossRefGoogle Scholar
  13. 13.
    Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–92.CrossRefGoogle Scholar
  14. 14.
    Chang YP, Chen CL, Chen SO, et al. Autophagy facilitates an IFN-gamma response and signal transduction. Microbes Infect. 2011;13(11):888–94.CrossRefGoogle Scholar
  15. 15.
    Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462.  https://doi.org/10.1080/2162402X.2016.1163462.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol. 2014;10:207–17.CrossRefGoogle Scholar
  17. 17.
    Wang Q, Luan W, Warren L, Kadri H, Kim KW, Goz V, Blank S, Isabel Fiel M, Hiotis SP. Autologous tumor cell lysate-loaded dendritic cell vaccine inhibited tumor progression in an orthotopic murine model for hepatocellular carcinoma. Ann Surg Oncol. 2016;23(Suppl 5):574–82.CrossRefGoogle Scholar
  18. 18.
    Fecek RJ, Storkus WJ. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy. 2016;8(10):1205–18.CrossRefGoogle Scholar
  19. 19.
    Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol. 2017;23(29):5395–404.CrossRefGoogle Scholar
  20. 20.
    Zeng J, Huang X, Zhou L, et al. Metabolomics identifies biomarker pattern for early diagnosis of hepatocellular carcinoma: from diethylnitrosamine treated rats to patients. Sci Rep. 2015;5:16101.  https://doi.org/10.1038/srep16101.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Markov OV, Mironova NL, Sennikov SV, Vlassov VV, Zenkova MA. Prophylactic dendritic cell-based vaccines efficiently inhibit metastases in murine metastatic melanoma. PLoS ONE. 2015;10(9):e0136911.  https://doi.org/10.1371/journal.pone.0136911.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lasky JL 3rd, Panosyan EH, Plant A, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res. 2013;33(5):2047–56.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Fleury P, Eberhard R. Determination of proteins in human milk by the biuret technic. Ann Biol Clin (Paris). 1955;13(1–2):1–7.Google Scholar
  24. 24.
    Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS ONE. 2010.  https://doi.org/10.1371/journal.pone.0011144.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Magalhães A, Ferreira KS, Almeida SR, Nosanchuk JD, Travassos LR, Taborda CP. Prophylactic and therapeutic vaccination using dendritic cells primed with peptide 10 derived from the 43-kilodalton glycoprotein of Paracoccidioides brasiliensis. Clin Vaccine Immunol. 2012;19(1):23–9.CrossRefGoogle Scholar
  26. 26.
    Palucka K, Banchereau J. Dendritic cell-based cancer therapeutic vaccines. Immunity. 2013;39(1):38–48.CrossRefGoogle Scholar
  27. 27.
    El-Ashmawy NE, El-Bahrawy HA, Shamloula MM, El-Feky OA. Biochemical/metabolic changes associated with hepatocellular carcinoma development in mice. Tumour Biol. 2014;35(6):5459–66.CrossRefGoogle Scholar
  28. 28.
    Garg AD, Vandenberk L, Koks C, et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med. 2016;8(328):328ra27.  https://doi.org/10.1126/scitranslmed.aae0105.CrossRefPubMedGoogle Scholar
  29. 29.
    Schmidt K, Seeger K, Scheibenbogen C, et al. Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia. J Leukoc Biol. 2009;85(3):563–73.CrossRefGoogle Scholar
  30. 30.
    Mehrotra S, Britten CD, Chin S, et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol. 2017;10(1):82.CrossRefGoogle Scholar
  31. 31.
    Farashi-Bonab S, Khansari N. Anticancer dendritic cell vaccines producing effective antitumor T Cell responses. Int J Vaccines Vaccin. 2017;4(3):00081.Google Scholar
  32. 32.
    Waldmann TA. Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol. 2017;pii:a028472.  https://doi.org/10.1101/cshperspect.a028472.CrossRefGoogle Scholar
  33. 33.
    Ashrafi S, Shapouri R, Mahdavi M. Immunological consequences of immunization with tumor lysate vaccine and propranolol as an adjuvant: a study on cytokine profiles in breast tumor microenvironment. Immunol Lett. 2017;181:63–70.CrossRefGoogle Scholar
  34. 34.
    Rainone V, Martelli C, Ottobrini L, et al. Immunological characterization of whole tumor lysate-loaded dendritic cells for cancer immunotherapy. PLoS ONE. 2016;11(1):e0146622.  https://doi.org/10.1371/journal.pone.0146622.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Mendoza L, Bubeník J, Símová J, Jandlová T, Vonka V, Mikysková R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol. 2003;23:243–7.PubMedGoogle Scholar
  36. 36.
    Samadi-Foroushani M, Vahabpour R, Memarnejadian A, et al. Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination. Med Oncol. 2011;28(Suppl 1):S660–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Nahla E. El-Ashmawy
    • 1
  • Enas A. El-Zamarany
    • 2
  • Eman G. Khedr
    • 1
  • Hoda A. El-Bahrawy
    • 1
  • Ola A. El-Feky
    • 1
  1. 1.Department of Biochemistry, Faculty of PharmacyTanta UniversityTantaEgypt
  2. 2.Department of Clinical Pathology, Faculty of MedicineTanta UniversityTantaEgypt

Personalised recommendations